IDH1 mutation
1 drugsPredictive biomarker for patient selection in 3 indications
1
Approved Drugs
3
Indications
1
Companies
IDH1 mutation is a precision-medicine biomarker linked to 1 FDA-approved targeted drug from 1 company, spanning 3 indications including Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cholangiocarcinoma. Explore the targeted therapies, indications, testing methods, and companies developing IDH1 mutation drugs below.
Search IDH1 mutation Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting IDH1 mutation
| Drug | Company | Therapeutic Area |
|---|---|---|
| TIBSOVO | SERVIER | Oncology |